Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2021-08-26 Annual Report
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Full Year Statutory Accounts and Preliminary Final Report 51 pages 961.3KB
Annual Report Classification · 100% confidence The document is a detailed communication from Biotron Limited dated 27 August 2021, containing the Year End Accounts and Appendix 4E Preliminary Final Report for the year ended 30 June 2021. It explicitly states that the Annual Report forms part of this Preliminary Final Report. The document includes extensive financial and operational review content, such as Operating and Financial Review, Corporate Governance Statement, Directors' Report, financial statements, auditor's report, and other typical annual report sections. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. The presence of the Appendix 4E Preliminary Final Report and the full Annual Report for the fiscal year ending 30 June 2021 confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K).
2021-08-26 English
Quarterly Appendix 4C Cash Flow Report 5 pages 160.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities, as well as reconciliation of cash and cash equivalents. It references the ASX Listing Rules and provides financial data for the quarter ended 30 June 2021. The document is over 10,000 characters, indicating it is a full report rather than a brief announcement. The content matches the characteristics of a comprehensive interim or quarterly financial report with substantive financial data and analysis. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2021-07-29 English
Quarterly Activities Report 2 pages 146.0KB
Interim / Quarterly Report Classification · 90% confidence The document is titled 'REPORT ON ACTIVITIES FOR THE QUARTER ENDED 30 JUNE 2021' and details the company's progress on various research and development programs during the quarter. It includes financial expenditure details and cash position but does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report. The document is about quarterly activities and progress rather than a full financial report. It is a quarterly activities report commonly filed as a quarterly update to the stock exchange (ASX). Given the content and length (5155 characters), it fits the profile of an Interim / Quarterly Report (IR) rather than a brief announcement or a full annual report. Therefore, the classification is IR with high confidence.
2021-07-29 English
Letter to Shareholders 3 pages 251.2KB
Management Reports Classification · 95% confidence The document is titled 'SHAREHOLDER UPDATE' and is addressed to shareholders, providing detailed progress updates on clinical trials, drug development programs, and financial position. It is a narrative update rather than a formal financial report or regulatory filing. The document does not contain financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It also does not announce voting results, management changes, or capital structure changes. The content focuses on business progress and outlook, which aligns with a Management Report (MDA) that explains business trends and outlook to shareholders. The length (9145 characters) and detailed content support this classification rather than a brief announcement or presentation. Therefore, the document is best classified as a Management Report (MDA).
2021-07-07 English
Notification of cessation of securities - BIT 4 pages 24.3KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation of securities, specifically options that have expired unexercised under the Employee Option Plan. It provides details about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement related to changes in the company's issued capital and securities status, not a full financial report or detailed management discussion. It does not contain financial statements or detailed analysis but is a regulatory announcement about securities status changes. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-06-30 English
$1.4M R&D Tax Rebate 2 pages 121.2KB
Regulatory Filings Classification · 95% confidence The document is a short announcement (2020 characters) from Biotron Limited regarding receipt of an R&D Tax Incentive refund for the 2019/20 financial year. It includes no financial statements or detailed financial data, only a notification of receipt of a government tax refund. The document is addressed to the ASX and is an announcement of a specific financial event (R&D tax refund) rather than a full financial report or detailed filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a certification or officer attestation. Given its nature as a brief regulatory announcement about a financial incentive refund, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Confidence is high due to clear content and short length indicating an announcement rather than a report.
2021-04-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.